Comparative Pharmacology
Head-to-head clinical analysis: CLOXACILLIN SODIUM versus CYCLAPEN W.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXACILLIN SODIUM versus CYCLAPEN W.
CLOXACILLIN SODIUM vs CYCLAPEN-W
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxacillin is a beta-lactam antibiotic that binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidases and thus preventing the cross-linking of peptidoglycan chains. This leads to cell lysis and death, primarily mediated by autolytic enzymes. It is resistant to penicillinase (beta-lactamase) produced by staphylococci.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
250-500 mg orally every 6 hours on an empty stomach; 250 mg - 2 g IV/IM every 4-6 hours depending on severity; maximum 12 g/day for serious infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
0.5-1.1 hours in adults with normal renal function; prolonged in neonates, elderly, and renal impairment (up to 2-4 hours in anuria)
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Renal (70-80% unchanged via glomerular filtration and tubular secretion); biliary/fecal (small amount, <10%)
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic